Novo Holdings today announced that Britt Meelby Jensen has been elected to join the Board of Novo Holdings. Britt Meelby Jensen will be continuing in her role in the Novo Advisory Group, where she has served since 2020.

“I am very pleased to welcome Britt to the Novo Holdings Board of Directors,” said Lars Rebien Sørensen, Chairman of the Boards of Novo Holdings and the Novo Nordisk Foundation. “Britt is a highly competent and experienced life sciences leader, and I am delighted that she will join the Board, where she will continue contributing to our efforts in generating returns to our owner, the Novo Nordisk Foundation.”

Britt has over twenty years of experience from the life science industry, pharma, diagnostics, biotech and medtech. From 2019 to early 2022, Britt Meelby Jensen served as CEO of Atos Medical AB. In connection with selling the company to Coloplast, Britt decided to step down as CEO to continue as an adviser as of March 2022. From 2015 to 2019, Britt Meelby Jensen was President and CEO of Zealand Pharma A/S. During her leadership, the company was listed on Nasdaq in the US. Prior to this, Britt Meelby Jensen  served as CEO for Dako A/S in 2013-2014.

Britt Meelby Jensen joined Novo Nordisk A/S in 2002, where she assumed several leadership roles, including the role of Corporate Vice President of Global Marketing, Market Access & Commercial Excellence. Between 2000 and 2002, Britt Meelby Jensen served as Management Consultant with McKinsey & Company.

“Novo Holdings is a globally leading life science investor that, in addition to generating significant returns, delivers societal impact through investments in healthcare and bioindustrials. I am very excited to join the Board of Directors and contribute to the future growth of Novo Holdings,” said Britt Meelby Jensen.

Britt Meelby Jensen is a Danish citizen. She holds a MSc in International Marketing and Management from Copenhagen Business School and has earned an MBA from Solvay Business School (Université Libre de Bruxelles).

Board positions and management duties:

• Board Member, Ambu A/S, Denmark

• Board Member, Hempel Foundation and Hempel Invest A/S, Denmark

• Steering Committee Member, Women Corporate Directors (WCD), Denmark

• Member, Danish Competitiveness Council (Dansk Konkurrenceevneråd)

• Jury Member, Entrepreneur of the Year, Life Science category

**About Novo Holdings A/S
**Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation’s assets.

Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Further information: www.novoholdings.dk.

**About the Novo Nordisk Foundation
**The Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives established in Denmark in 1924. The vision of the Foundation is to improve people’s health and the sustainability of society and the planet. The Foundation’s mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society. Further information:

www.novonordiskfonden.dk/en

**Further information
**Marie-Louise Jersin, Senior Communications Partner, +45 3049 4957, maj@novo.dk